Integra LifeSciences reported third-quarter 2026 revenue of $411.2 million, up 2.3% from the prior year, and GAAP earnings of $0.19 per diluted share versus a loss of $(0.07) a year earlier. The company kept its full-year 2026 guidance consistent with its October 2, 2026 outlook, but expects fourth-quarter reported revenue to decline 0.5% to 5.2%, citing the Cincinnati facility disruption and softer Tissue Reconstruction results.
Q3 revenue $411.2 million, up 2.3% reported and 2.5% organic; GAAP EPS $0.19 vs. $(0.07), adjusted EPS $0.59 vs. $0.54
Full-year 2026 revenue guidance $1.634 billion to $1.654 billion; adjusted EPS guidance $2.30 to $2.40, consistent with October 2, 2026 outlook
Fourth-quarter 2026 adjusted EPS guidance $0.61 to $0.71; reported revenue expected to decline 0.5% to 5.2%
Completed $2.1 billion debt refinancing on October 19, 2026; Q3 operating cash flow $96.0 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Integra Lifesciences Holdings's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$1.64B
+1.5%
$-6.74
—
-31.6%
FY2024
$1.61B
+4.5%
$-0.09
-110.7%
-0.4%
FY2023
$1.54B
-1.0%
$0.84
-61.1%
4.4%
FY2022
$1.56B
+1.0%
$2.16
+9.1%
11.6%
FY2021
$1.54B
+12.4%
$1.98
+26.1%
11.0%
Frequently asked questions
When is Integra Lifesciences's next earnings date?
Integra Lifesciences has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Integra Lifesciences earn last quarter?
For the quarter ended Sep 2026, Integra Lifesciences reported diluted EPS of $0.19 on revenue of $411.18M (+2.3%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.